- $39.13bn
- $38.58bn
- $5.15bn
- 99
- 30
- 79
- 80
Annual balance sheet for Resmed, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 295 | 274 | 228 | 238 | 1,209 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 625 | 602 | 736 | 875 | 991 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 1,575 | 1,931 | 2,368 | 2,358 | 3,506 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 592 | 630 | 666 | 699 | 718 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 4,728 | 5,096 | 6,752 | 6,872 | 8,174 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 912 | 689 | 759 | 911 | 1,019 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 1,842 | 1,735 | 2,622 | 2,008 | 2,207 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 2,886 | 3,361 | 4,130 | 4,864 | 5,968 |
| Total Liabilities & Shareholders' Equity | 4,728 | 5,096 | 6,752 | 6,872 | 8,174 |
| Total Common Shares Outstanding |